Thus, selectively targeting CREPT expression may provide alternative strategies for inhibiting abnormal cell division, metastasis, and tumor growth, and may improve the efficacy of the currently available therapies in combination, and will be key to reversing cancerous growth in patients with CREPT-driven cancers. This evidence concerns the gene RPRD1B and neoplasm.